Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

nth period ended September 30, 2007 included a one-time, up-front recognition of $13.0 million related to the approval milestone for SANCTURA XR from Allergan.

Cost of product revenue for the quarter ended September 30, 2008 was $10.7 million, an increase of 91% from the $5.6 million reported for the quarter ended September 30, 2007. Cost of product revenue relates primarily to sales of SANCTURA and SANCTURA XR to Allergan at cost, royalties on sales of SANCTURA and SANCTURA XR that are reimbursed by Allergan, and costs associated with VANTAS, SUPPRELIN LA and DELATESTRYL.

Research and development expenses for the quarter ended September 30, 2008 were $7.1 million, a decrease of 43% from the $12.4 million reported for the quarter ended September 30, 2007. Marketing, general and administrative expenses for the quarter ended September 30, 2008 were $16.2 million, a decrease of 13% from the $18.7 million reported for the quarter ended September 30, 2007.

Conference call and webcast

The live call may be accessed by dialing 866-543-6403 from the U.S. and Canada, and 617-213-8896 from international locations. The participant passcode is 92405431. Investors are advised to dial into the call at least ten minutes prior to the call to register. A replay of the call will be available beginning at 11:00 AM on November 25, 2008 and lasting until 12:00 AM on December 23, 2008. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 49937348.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com. An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceutica
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Sept. 16, 2014  The Council for Entrepreneurial ... organization in the country, today released a mid-year ... It showed that in the ... startups in the technology, life science, ... investment from a variety of sources. Significant investment in ...
(Date:9/16/2014)... Arizona (PRWEB) September 16, 2014 ... develops safe and effective products to treat patients ... use of a proprietary SPACEā„¢ Technology Platform announced ... and President will present at the White Hat ... at the Hyatt Regency Phoenix. In addition, ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... , June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for ... for treating cell proliferative disorders by administering modified vaccinia virus to ... , , ...
... June 17 ChemoCentryx, Inc., today announced that ... drug candidate CCX354 at the Annual European Congress of ... drug candidate designed to specifically target the CCR1 chemokine ... (RA).  Data demonstrating that CCX354 was safe and well ...
... Researchers at Rensselaer Polytechnic Institute have developed a ... that measure only billionths of a meter thick. ... works on nearly any surface including silicon wafers, ... manufacturing. Sang-Kee Eah, assistant professor in the ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 3ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 4Researchers develop ultra-simple method for creating nanoscale gold coatings 2
(Date:9/17/2014)... their environmental impact recently scored a major win. In ... the bags, and Governor Jerry Brown is expected to ... yielding without a fight, according to an article in ... of the American Chemical Society. , Alexander Tullo, a ... logged its first small victory in 1990 when Nantucket ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... in Biomedical Informatics at IMIM (Hospital del Mar Medical ... (UPC) have recently published a study in eLife ... important role in the evolution of new proteins, some ... be discovered., Ribosomes produce proteins from the instructions found ... human genome is RNA containing information for the synthesis ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
... mountain meadows in the Pacific Northwest are declining rapidly due ... growing seasons and other factors allow trees to invade these ... wildflowers. The process appears to have been going on ... Jefferson Park, a subalpine meadow complex in the central Oregon ...
... Planck Institute for Chemical Energy Conversion (MPI CEC) and ... on a hydrogen-producing enzyme that the environment of the ... enzyme. Thus, it can very efficiently produce hydrogen, which ... research team describes their results in the journal " ...
... Calif.During the early developmental stages of vertebratesanimals that ... undergo extensive rearrangements, and some cells migrate over ... novel roles as differentiated cell types. Understanding how ... an embryo is an important and complex goal ...
Cached Biology News:Mountain meadows dwindling in the Pacific Northwest 2Temporary storage for electrons: Natural method of producing hydrogen 2Developmental bait and switch 2Developmental bait and switch 3
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
SHEEP ANTI HUMAN CATHEPSIN G...
Request Info...
RABBIT ANTI TRANSFERRIN RECEPTOR...
Biology Products: